Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Acute leukaemia, Acute lymphoblastic leukaemia (ALL), Blood cancers, Children's cancers, Leukaemia
Closed
Phase 1/2
This trial is looking at combining selumetinib with dexamethasone for children and adults with acute lymphoblastic leukaemia (ALL).
It is open to people with ALL that has come back after treatment (relapsed) or has continued to get worse during treatment (refractory). And the leukaemia has a gene change (mutation) in the RAS-pathway that controls the MEK protein.
Cancer Research UK supports this trial.
Recruitment start: 17 April 2018
Recruitment end: 31 December 2022
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Tobias Menne
AstraZeneca
Cancer Research UK
University of Birmingham
Last reviewed: 4 August 2024
CRUK internal database number: 14315
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
